In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fragrance Foundation’s Green retiring

This article was originally published in The Rose Sheet

Executive Summary

Effective in January, Annette Green stepping down as president of the Fragrance Foundation after more than 40 years of running the organization. She will continue to be associated with the foundation for two years, primarily dedicating her time to work with the fragrance museum. Prior to being named president in 1992, Green had served as executive director of the non-profit educational organization since 1961. No successor has been announced...

You may also be interested in...

Fragrance Foundation award

Outgoing President Annette Green to be inducted into Fragrance Foundation's "Circle of Champions" at third annual award ceremony, to be held in New York City Nov. 4. She will join previous inductees, Leonard Lauder and Guy Peyrelongue, who were honored in 2000 and 2001, respectively. Green is planning to step down as president at end of year, after over four decades at the Fragrance Foundation (1"The Rose Sheet" June 10, 2002, In Brief). Following her retirement, she will act as consultant to her yet-unannounced successor over the next two years...

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts